Variation in Naloxone and Buprenorphine Prescribing in LA County's Safety-Net System
ResearchPosted on rand.org Jan 16, 2026Published in: Journal of Opioid Management, Volume 21, No. 6, pages 477-481 (November/December 2025). DOI: 10.5055/jom.0960
ResearchPosted on rand.org Jan 16, 2026Published in: Journal of Opioid Management, Volume 21, No. 6, pages 477-481 (November/December 2025). DOI: 10.5055/jom.0960
To describe patients and visits with identified, probable opioid use disorder (OUD) in Los Angeles County’s (LAC) safety-net system and examine rates of naloxone and buprenorphine prescribing across healthcare settings.
A descriptive analysis of electronic health record data. Setting: LAC’s largest safety-net provider, the LAC Department of Health Services.
This study included 3,881 patients with 5,580 visits involving probable OUD from July 2022 to June 2023.
Visit-level analysis was performed to identify treatment settings where patients accessed care. We compared rates of buprenorphine and naloxone prescription across treatment settings using Chi-square tests and 95 percent confidence intervals.
Visits with identified OUD most often occurred in outpatient settings (36 percent) compared to inpatient (31 percent), emergency (24 percent), or urgent care (8 percent) settings. Overall, 35.8 percent of visits included a naloxone prescription, and 30.4 percent included a buprenorphine prescription. Prescription rates varied significantly by treatment setting.
Most visits with probable OUD did not include naloxone or buprenorphine prescriptions, and prescription receipt varied by setting.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.